



BMA BIOMEDICALS



Peninsula Laboratories

T-4239

**Rabbit anti α -Calcitonin Gene-Related Peptide (human)
[UniProt: P06881]**

α -Calcitonin Gene-Related Peptide (α -CGRP) is a regulatory neuropeptide of 37 amino acids and is formed by the alternative splicing of the calcitonin / CGRP gene located on chromosome 11. It is widely distributed in both the peripheral and central nervous system, predominantly in cell bodies of the dorsal root ganglion (DRG) and it is known to be a potent vasodilator with inotropic and chronotropic effects.

This antibody was generated by immunization of rabbits with α -Calcitonin Gene-Related Peptide coupled to a carrier protein.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Lot number:	A18PO23092
Host species:	Rabbit IgG
Quantity:	50 μ l
Format:	Neat undiluted antiserum, lyophilized, packaged under nitrogen. Reconstitute by adding 50 μ l distilled water. This will give the equivalent of undiluted antiserum.
Stability:	Original vial: at least one year at 4° - 8°C from date of delivery. Minimize repeated thawing and freezing of the antiserum by freezing aliquots at -20°C or below.
Applications:	This antibody has been tested and validated in ELISA against α -CGRP and in immunohistochemistry (IHC). Other applications like FACS or Western Blot may work as well. Optimal dilutions should be determined by the end user. Please see www.bma.ch for protocols and general information.
Immunogen:	Synthetic peptide H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH ₂ , (Disulfide bond) coupled to carrier protein.

Typical titration curve of α -CGRP in a competitive ELISA with this antibody:

Related Products: T-4238: anti α -CGRP (hu), purified IgG, host: rabbit
T-5027: anti α -CGRP (hu) neat antiserum, host: guinea pig
S-1198: α -CGRP (hu) ELISA, extraction-free for serum/plasma samples

For in vitro research only. This product contains no preservative. Purchase of this product does not include authorization to use it in diagnostic or therapeutic applications.

T-4239

25/10/2023